Products
Platform
Research
Market
Learn
Compare ICICI Prudential Nifty Pharma Index Fund vs Nippon India Pharma Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 3.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 0.98 | 1.8 |
NAV | ₹17.33 | ₹530.79 |
Fund Started | 25 Nov 2022 | 10 May 2004 |
Fund Size | ₹91.49 Cr | ₹8569.15 Cr |
Exit Load | - | Exit load of 1% if redeemed within 1 month. |
Risk
Very High
Very High
Rating
-
3.0
Min SIP Amount
₹1000
₹100
Expense Ratio
0.98
1.8
NAV
₹17.33
₹530.79
Fund Started
25 Nov 2022
10 May 2004
Fund Size
₹91.49 Cr
₹8569.15 Cr
Exit Load
-
Exit load of 1% if redeemed within 1 month.
Returns
1 Year | 4.37% | 8.47% |
3 Year | - | 24.46% |
5 Year | - | 20.23% |
1 Year
4.37%
8.47%
3 Year
-
24.46%
5 Year
-
20.23%
Holding Analysis
Equity | 99.97% | 99.43% |
Cash | 0.03% | 0.57% |
Equity
99.97%
99.43%
Cash
0.03%
0.57%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 22.86% |
Divi's Laboratories Ltd. | 10.94% |
Cipla Ltd. | 10.71% |
Dr. Reddy's Laboratories Ltd. | 9.88% |
Lupin Ltd. | 5.93% |
Torrent Pharmaceuticals Ltd. | 4.51% |
Aurobindo Pharma Ltd. | 4.01% |
Laurus Labs Ltd. | 3.59% |
Alkem Laboratories Ltd. | 3.36% |
Glenmark Pharmaceuticals Ltd. | 3.34% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.23% |
Divi's Laboratories Ltd. | 8.50% |
Lupin Ltd. | 6.07% |
Cipla Ltd. | 5.62% |
Apollo Hospitals Enterprise Ltd. | 5.48% |
Dr. Reddy's Laboratories Ltd. | 5.18% |
Medplus Health Services Ltd. | 3.83% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.63% |
Narayana Hrudayalaya Ltd. | 3.55% |
Vijaya Diagnostic Centre Ltd. | 3.32% |
Fund Manager
Name | Kayzad Eghlim | Akshay Sharma |
Start Date | 03 Dec 2021 | 01 Dec 2022 |
Name
Kayzad Eghlim
Akshay Sharma
Start Date
03 Dec 2021
01 Dec 2022
About Fund
Description | The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. |
Launch Date | 25 Nov 2022 | 10 May 2004 |
Description
The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Launch Date
25 Nov 2022
10 May 2004
